INTERMEDICAL CARE AND LAB HOSPITAL |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.7 THB | +0.75% |
|
0.00% | -12.99% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Its low valuation, with P/E ratio at 8.7 and 5.93 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.99% | 38.98M | - | ||
| -19.34% | 16.41B | B+ | ||
| +5.41% | 12.64B | B | ||
| +4.64% | 11.75B | B+ | ||
| +2.58% | 10.04B | B+ | ||
| +29.17% | 8.68B | B | ||
| -2.49% | 7.68B | A- | ||
| +7.69% | 7.08B | D | ||
| +4.93% | 6.65B | B- | ||
| +44.78% | 4.46B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- IMH Stock
- Ratings Intermedical Care and Lab Hospital